ECM
FBRX icon

Endurant Capital Management’s Forte Biosciences FBRX Stock Holding History

Endurant Capital Management’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,135
Closed -$1.79M – 57
2021
Q2 		$1.79M Buy
2,135
+1,031
+93% +$929K 0.49% 50
2021
Q1 		$946K Buy
+1,104
New +$904K 0.25% 56

Other funds holding FBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
OQS
Occudo Quantitative Strategies Fort Lauderdale, Florida $1.84B AUM 22.15% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Endurant Capital Management's FBRX Position: Q3 2021 in Review

Endurant Capital Management sold out of Forte Biosciences (FBRX) in Q3 2021, closing a stake of 2,135 shares — an estimated $1.79M sold.

Endurant Capital Management first reported a position in FBRX in Q1 2021 and held it in 2 quarters. The position peaked at $1.79M in Q2 2021. 57 funds tracked by Wall St. Rank hold FBRX as of Q3 2021.

  • Endurant Capital Management reported no remaining Forte Biosciences position as of Q3 2021 after selling out during the quarter.
  • Endurant Capital Management sold 2,135 Forte Biosciences shares in Q3 2021, an estimated $1.79M.
  • Endurant Capital Management first reported a position in Forte Biosciences in Q1 2021 and held it in 2 quarters.
  • Endurant Capital Management's Forte Biosciences position peaked at $1.79M in Q2 2021.
  • 57 funds tracked by Wall St. Rank held Forte Biosciences as of Q3 2021.

Based on Endurant Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.